MYCN and neoplasm: Two Aurora-A kinase activity inhibitors, MLN8054 and MLN8237, disrupt the Aurora-A/N-MYC complex and promote FBXW7-mediated degradation of N-MYC, which correlates with tumor regression and prolonged survival in a mouse model of MYCN-driven neuroblastoma (122, 123).